Development and validation of a risk prediction model of vancomycin-associated nephrotoxicity in elderly patients: a pilot study.
This exploratory study aimed to develop a risk prediction model of vancomycin-associated nephrotoxicity (VANT) in elderly patients. Clinical information of elderly patients who received vancomycin therapy from January 2016 to June 2018 was retrieved. A total of 255 patients were included in this study. Univariate analysis and multivariable logistic regression analysis revealed that vancomycin trough concentration ≥ 20mg/L (OR = 3.009; 95%CI 1.345~6.732), surgery (OR = 3.357; 95%CI 1.309~8.605), the Charlson comorbidities index (CCI) ≥4 points (OR = 2.604; 95%CI 1.172~5.787), concomitant usage of cardiotonics (OR = 3.283; 95%CI 1.340~8.042), plasma volume expander (OR = 3.459; 95%CI 1.428~8.382) and piperacillin/tazobactam (PTZ) (OR = 2.547; 95%CI 1.680~6.007) were risk factors for VANT in elderly patients. Furthermore, a VANT risk prediction model was developed, which had good discriminative power and was well-calibrated.